Drug Database · Clinicians

Temozolomide

Brands (18) Astrodal, Tamina, Gliotem 100…Show all

US brand (reference label): TEMODAR; not a Philippine-registered brand.

Alkylating Drug (Alkylating Activity) US FDA class
Antineoplastic (alkylating agent); Antineoplastic agent PH FDA category

Rx · Prescription drug22 PH productsVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 046a9011-3911-4d3f-a15f-fbb56d5aad56, version date February 20, 2026 (TEMODAR · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.
  • Anaplastic astrocytoma.
  • Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma.
  • Treatment of adults with refractory anaplastic astrocytoma.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE TEMODAR is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. (1.1) Anaplastic astrocytoma. (1.2) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. (1.2) Treatment of adults with refractory anaplastic astrocytoma.

(1.2) 1.1 Newly Diagnosed Glioblastoma TEMODAR is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMODAR is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.

Contraindications

4 CONTRAINDICATIONS TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. Reactions to TEMODAR have included anaphylaxis [see Adverse Reactions (6.2)]. History of serious hypersensitivity to temozolomide or any other ingredients in TEMODAR and dacarbazine. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Administer either orally or intravenously. (2.4)
  • Newly Diagnosed Glioblastoma: 75 mg/m 2 once daily for 42 to 49 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m 2 once daily for Days 1 to 5 of each 28-day cycle for 6 cycles. May increase maintenance dose to 200 mg/m 2 for Cycles 2 to 6 based on toxicity. (2.1)
  • Provide Pneumocystis pneumonia (PCP) prophylaxis during concomitant phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less. (2.1)
  • Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma: Beginning 4 weeks after the end of radiotherapy, administer TEMODAR orally in a single dose on days 1-5 of a 28-day cycle for 12 cycles. The recommended dosage for Cycle 1 is 150 mg/m 2 per day and for Cycles 2 to 12 is 200 mg/m 2 if patient experienced no or minimal toxicity in Cycle 1. (2.2)
  • Refractory Anaplastic Astrocytoma: Initial dose of 150 mg/m 2 once daily on Days 1 to 5 of each 28-day cycle. (2.2)
2.1 Monitoring

2.1 Monitoring to Inform Dosage and Administration Prior to dosing, withhold TEMODAR until patients have an absolute neutrophil count (ANC) of 1.5 x 10 9 /L or greater and a platelet count of 100 x 10 9 /L or greater. For concomitant radiotherapy, obtain a complete blood count prior to initiation of treatment and weekly during treatment.

For the 28-day treatment cycles, obtain a complete blood count prior to treatment on Day 1 and on Day 22 of each cycle. Perform complete blood counts weekly until recovery if the ANC falls below 1.5 x 10 9 /L and the platelet count falls below 100 x 10 9 /L. For concomitant use with focal radiotherapy, obtain a complete blood count weekly and as clinically indicated.

2.2 Recommended Dosage

2.2 Recommended Dosage and Dosage Modifications for Newly Diagnosed Glioblastoma Administer TEMODAR either orally or intravenously once daily for 42 to 49 consecutive days during the concomitant use phase with focal radiotherapy, and then once daily on Days 1 to 5 of each 28-day cycle for 6 cycles during the maintenance use phase. Provide Pneumocystis pneumonia (PCP) prophylaxis during the concomitant use phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less [see Warnings and Precautions (5.3)].

Concomitant Use Phase: The recommended dosage of TEMODAR is 75 mg/m 2 either orally or intravenously once daily for 42 to 49 days in combination with focal radiotherapy. Focal radiotherapy includes the tumor bed or resection site with a 2 to 3 cm margin. Other administration schedules have been used. Obtain a complete blood count weekly.

The recommended dosage modifications due to adverse reactions during concomitant use phase are provided in Table 1. TABLE 1: Dosage Modifications Due to Adverse Reactions During Concomitant Use Phase Adverse Reaction Interruption Discontinuation Absolute Neutrophil Count Withhold TEMODAR if ANC is greater than or equal to 0.5 × 10 9 /L and less than 1.5 × 10 9 /L.

Discontinue TEMODAR if ANC is less than 0.5 × 10 9 /L. Resume TEMODAR at the same dose when ANC is greater than or equal to 1.5 × 10 9 /L. Platelet Count Withhold TEMODAR if platelet count is greater than or equal to 10 × 10 9 /L and less than 100 × 10 9 /L. Discontinue TEMODAR if platelet count is less than 10 × 10 9 /L.

Resume TEMODAR at the same dose when platelet count is greater than or equal to 100 × 10 9 /L. Non-hematological Adverse Reaction (except for alopecia, nausea, vomiting) Withhold TEMODAR if Grade 2 adverse reaction occurs. Discontinue TEMODAR if Grade 3 or 4 adverse reaction occurs. Resume TEMODAR at the same dose when resolution to Grade 1 or less.

Single Agent Maintenance Use Phase: Beginning 4 weeks after concomitant use phase completion, administer TEMODAR either orally or intravenously once daily on Days 1 to 5 of each 28-day cycle for 6 cycles. The recommended dosage of TEMODAR in the maintenance use phase is: Cycle 1: 150 mg/m 2 per day on days 1 to 5. Cycles 2 to 6: May increase to 200 mg/m 2 per day on days 1 to 5 before starting Cycle 2 if no dosage interruptions or discontinuations are required (Table 1).

If the dose is not escalated at the onset of Cycle 2, do not increase the dose for Cycles 3 to 6. Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 × 10 9 /L and the platelet count is above 100 × 10 9 /L. Do not start the next cycle until the ANC and platelet count exceed these levels. The recommended dosage modifications due to adverse reactions during the maintenance use phase are provided in Table 2.

If TEMODAR is withheld, reduce the dose for the next cycle by 50 mg/m 2 per day. Permanently discontinue TEMODAR in patients who are unable to tolerate a dose of 100 mg/m 2 per day. TABLE 2: Dosage Modifications Due to Adverse Reactions During Maintenance and Adjuvant Treatment Adverse Reactions Interruption and Dose Reduction Discontinuation Absolute Neutrophil Count Withhold TEMODAR if ANC less than 1 × 10 9 /L.

Discontinue TEMODAR if unable to tolerate a dose of 100 mg/m 2 per day. When ANC is above 1.5 × 10 9 /L, resume TEMODAR at reduced dose for the next cycle. Platelet Count Withhold TEMODAR if platelet less than 50 × 10 9 /L. Discontinue TEMODAR if unable to tolerate a dose of 100 mg/m 2 per day. When platelet count is above 100 × 10 9 /L, resume TEMODAR at reduced dose for the next cycle.

Nonhematological Adverse Reactions (except for alopecia, nausea, vomiting) Withhold TEMODAR if Grade 3 adverse reaction occurs. Discontinue TEMODAR if recurrent Grade 3 adverse reaction occurs after dose reduction, if Grade 4 adverse reaction occurs, or if unable to tolerate a dose of 100 mg/m 2 per day. When resolved to Grade 1 or less, resume TEMODAR at reduced dose for the next cycle.

2.3 Recommended Dosage

2.3 Recommended Dosage and Dosage Modifications for Anaplastic Astrocytoma Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma Beginning 4 weeks after the end of radiotherapy, administer TEMODAR orally in a single dose on days 1 to 5 of a 28-day cycle for 12 cycles. The recommended dosage of TEMODAR is: Cycle 1: 150 mg/m 2 per day on days 1 to 5.

Cycles 2 to 12: 200 mg/m 2 per day on days 1 to 5 if patient experienced no or minimal toxicity in Cycle 1. If the dose was not escalated at the onset of Cycle 2, do not increase the dose during Cycles 3 to 6. The recommended complete blood count testing and dosage modifications due to adverse reactions during adjuvant treatment are provided above and in Table 2 [see Dosage and Administration (2.2)].

Refractory Anaplastic Astrocytoma The recommended initial dosage of TEMODAR is 150 mg/m 2 once daily on Days 1 to 5 of each 28-day cycle. Increase the TEMODAR dose to 200 mg/m 2 per day if the following conditions are met at the nadir and on Day 1 of the next cycle: ANC is greater than or equal to 1.5 × 10 9 /L, and Platelet count is greater than or equal to 100 × 10 9 /L.

Continue TEMODAR until disease progression or unacceptable toxicity. Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 x 10 9 /L and the platelet count is above 100 x 10 9 /L. Do not start the next cycle until the ANC and platelet count exceed these levels. If the ANC is less than 1 × 10 9 /L or the platelet count is less than 50 × 10 9 /L during any cycle, reduce the TEMODAR dose for the next cycle by 50 mg/m 2 per day.

Permanently discontinue TEMODAR in patients who are unable to tolerate a dose of 100 mg/m 2 per day.

2.4 Preparation and Administration

2.4 Preparation and Administration TEMODAR is a hazardous drug. Follow applicable special handling and disposal procedures. 1 TEMODAR capsules Take TEMODAR at the same time each day. Administer TEMODAR consistently with respect to food (fasting vs. nonfasting) [see Clinical Pharmacology (12.3)]. To reduce nausea and vomiting, take TEMODAR on an empty stomach or at bedtime and consider antiemetic therapy prior to and following TEMODAR administration.

Swallow TEMODAR capsules whole with water. Advise patients not to open, chew, or dissolve the contents of the capsules [see Warnings and Precautions (5.6)]. If capsules are accidentally opened or damaged, take precautions to avoid inhalation or contact with the skin or mucous membranes. In case of powder contact, wash the affected area with water immediately.

TEMODAR for injection Bring the vial to room temperature prior to reconstitution with Sterile Water for Injection. Reconstitute the vial with 41 mL of Sterile Water for Injection to yield a TEMODAR solution with a concentration of 2.5 mg/mL temozolomide. Reconstituted TEMODAR is a clear solution and essentially free of visible particles.

Gently swirl vial. Do not shake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if particulate matter or discoloration is observed. Do not further dilute the reconstituted solution. Store reconstituted solution at room temperature (25°C [77°F]).

Discard reconstituted solution if not used within 14 hours, including infusion time. Withdraw up to 40 mL from each vial to make up the total dose and discard any unused portion. Transfer reconstituted solution from each vial into an empty 250 mL infusion bag. Administer reconstituted solution using a pump over a period of 90 minutes.

Administer TEMODAR by intravenous infusion only. Infusion over a shorter or longer period of time may result in suboptimal dosing. Flush the lines before and after each infusion. TEMODAR for injection may be administered in the same intravenous line with 0.9% Sodium Chloride injection only. Because no data are available on the compatibility of TEMODAR for injection with other intravenous substances or additives, do not infuse other medications simultaneously through the same intravenous line.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment No dosage adjustment is recommended for patients with creatinine clearance (CLcr) of 36 to 130 mL/min/m 2 [see Clinical Pharmacology (12.3)]. The recommended dose of TEMODAR has not been established for patients with severe renal impairment (CLcr <36 mL/min/m 2) or for patients with end-stage renal disease on dialysis.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment No dosage adjustment is recommended for patients with mild to moderate hepatic impairment (Child Pugh class A and B) [see Clinical Pharmacology (12.3)]. The recommended dose of TEMODAR has not been established for patients with severe hepatic impairment (Child-Pugh class C).

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of TEMODAR have not been established in pediatric patients. Safety and effectiveness of TEMODAR capsules were assessed, but not established, in 2 open-label studies in pediatric patients aged 3 to 18 years. In one study, 29 patients with recurrent brain stem glioma and 34 patients with recurrent high-grade astrocytoma were enrolled.

In a second study conducted by the Children's Oncology Group (COG), 122 patients were enrolled, including patients with medulloblastoma/PNET (29), high grade astrocytoma (23), low grade astrocytoma (22), brain stem glioma (16), ependymoma (14), other CNS tumors (9), and non-CNS tumors (9). The adverse reaction profile in pediatric patients was similar to adults.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In MK-7365-051, 15% of patients with newly diagnosed glioblastoma were 65 years and older. This study did not include sufficient numbers of patients aged 65 years and older to determine differences in effectiveness from younger patients. No overall differences in safety were observed between patients ≥65 years and younger patients.

The CATNON trial did not include sufficient numbers of patients aged 65 years and older to determine differences in safety or effectiveness when compared to younger patients. In MK-7365-006, 4% of patients with refractory anaplastic astrocytoma were 70 years and older. This study did not include sufficient numbers of patients aged 70 years and older to determine differences in effectiveness from younger patients.

Patients 70 years and older had a higher incidence of Grade 4 neutropenia (25%) and Grade 4 thrombocytopenia (20%) in the first cycle of therapy than patients less than 70 years of age [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 10% (6/63) of patients >70 years experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively.

For patients ≤70 years, 7% (62/871) and 6% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia also occurred.

Administration

2.1 Monitoring to Inform Dosage and Administration Prior to dosing, withhold TEMODAR until patients have an absolute neutrophil count (ANC) of 1.5 x 10 9 /L or greater and a platelet count of 100 x 10 9 /L or greater. For concomitant radiotherapy, obtain a complete blood count prior to initiation of treatment and weekly during treatment. For the 28-day treatment cycles, obtain a complete blood count prior to treatment on Day 1 and on Day 22 of each cycle. Perform complete blood counts weekly until recovery if the ANC falls below 1.5 x 10 9 /L and the platelet count falls below 100 x 10 9 /L. For concomitant use with focal radiotherapy, obtain a complete blood count weekly and as clinically indicated.

2.4 Preparation and Administration TEMODAR is a hazardous drug. Follow applicable special handling and disposal procedures. 1 TEMODAR capsules Take TEMODAR at the same time each day. Administer TEMODAR consistently with respect to food (fasting vs. nonfasting) [see Clinical Pharmacology (12.3) ] . To reduce nausea and vomiting, take TEMODAR on an empty stomach or at bedtime and consider antiemetic therapy prior to and following TEMODAR administration. Swallow TEMODAR capsules whole with water. Advise patients not to open, chew, or dissolve the contents of the capsules [see Warnings and Precautions (5.6) ] . If capsules are accidentally opened or damaged, take precautions to avoid inhalation or contact with the skin or mucous membranes . In case of powder contact, wash the affected area with water immediately. TEMODAR for injection Bring the vial to room temperature prior to reconstitution with Sterile Water for Injection. Reconstitute the vial with 41 mL of Sterile Water for Injection to yield a TEMODAR solution with a concentration of 2.5 mg/mL temozolomide. Reconstituted TEMODAR is a clear solution and essentially free of visible particles. Gently swirl vial. Do not shake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if particulate matter or discoloration is observed. Do not further dilute the reconstituted solution. Store reconstituted solution at room temperature (25°C [77°F]). Discard reconstituted solution if not used within 14 hours, including infusion time. Withdraw up to 40 mL from each vial to make up the total dose and discard any unused portion. Transfer reconstituted solution from each vial into an empty 250 mL infusion bag. Administer reconstituted solution using a pump over a period of 90 minutes. Administer TEMODAR by intravenous infusion only. Infusion over a shorter or longer period of time may result in suboptimal dosing. Flush the lines before and after each infusion. TEMODAR for injection may be administered in the same intravenous line with 0.9% Sodium Chloride injection only. Because no data are available on the compatibility of TEMODAR for injection with other intravenous substances or additives, do not infuse other medications simultaneously through the same intravenous line.

US FDA label

Dosage forms

Philippines

  • Capsule: 20 mg, 100 mg, 250 mg
  • Hard gelatin capsule: 20 mg, 100 mg, 250 mg

Registered products in the Philippines

22 products registered with the Food and Drug Administration (FDA) Philippines list Temozolomide as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Temozolamide (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products22
Philippine FDA-registered products for Temozolomide
Package insert
AstrodalTemozolomide
100 mg CapsuleOne (1) capsule in aluminium foil sachet (Box of 5's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. Nantou PlantTaiwan
Metro Drug, Inc.
DR-XY47049
Dec 13, 2027
AstrodalTemozolomide
20 mg CapsuleAluminum foil sachet
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Lotus Healthcare Philippines Corporation.
DR-XY47048
Jan 30, 2029
AstrodalTemozolomide
20 mg CapsuleOne (1) capsule in aluminum foil sachet (Box of 5's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
LOTUS HEALTHCARE PHILIPPINES CORPORATION
DRP-15442
Sep 4, 2030
Gliotem 100Temozolomide
100 mg Hard Gelatin CapsuleType III Amber Glass Bottle x 30 mL (Capsule of 5's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-8739
Jul 10, 2031
Gliotem 20Temozolomide
20 mg Hard Gelatin CapsuleCold formed Alu-Alu (OPA/Alu/PVC laminate foil and Paper/PET/Alu lidding foil) Blister Pack x 5's (Box of 5's)
RxVAT-exempt
Sun Pharmaceutical Industries Limited.India
Sun Pharma Philippines, Inc.
DRP-9727
Apr 15, 2029
Gliotem 250Temozolomide
250 mg Hard Gelatin CapsuleCold formed Alu-Alu (OPA/Alu/PVC laminate foil and Paper/PET/Alu lidding foil) Blister Pack x 5's (Box of 5's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-8738
Apr 15, 2029
TaminaTemozolomide
100mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12604
Sep 13, 2027
TaminaTemozolomide
20mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12605
Sep 13, 2027
TaminaTemozolomide
250mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12603
Sep 13, 2027
TemoGetTemozolomide
100 mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-15722
Sep 13, 2029
Temoget-20Temozolomide
20 mg CapsuleHDPE Bottle x 5's (Box of 1 bottle)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-18529
Jul 29, 2031
TEMOLONTemozolomide
100 mg Capsule5 Capsules in HDPE Bottle (Box of 1's)
RxVAT-exempt
Celon Laboratories Pvt. Ltd.India
I.E MEDICA INC.
DRP-6021
Feb 20, 2030
Temolon 20Temozolomide
20 mg CapsuleHDPE Plastic Bottle x 5's (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica Inc.
DRP-4008
Feb 9, 2031
Temolon 250Temozolomide
250 mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica Inc.
DR-XY42326
Jul 31, 2028
Temosanz-100Temozolomide
100 mg CapsuleWhite, Opaque Child-Resistant HDPE Bottle with LDPE plug and Tamper-Evident HDPE Screw Cap Container with Desiccant and Cotton Plug (Bottle of 5's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Private Limited
DRP-7903
May 26, 2027
Temotero-100Temozolomide
100 mg CapsuleType I Amber Glass Bottle x 5's in a box
RxVAT-exempt
Hetero Labs Limited (Unit-V Block-VB)India
Camber Pharmaceuticals, Inc.
DRP-6721
Jun 2, 2030
Temotero-20Temozolomide
20 mg CapsuleType I Amber Glass Bottle x 5's (Box of 1's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-6720
Jun 20, 2028
Temovex 100Temozolomide
100 mg CapsuleHDPE Bottle x 5’s (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY43349
Apr 14, 2029
Temovex 20Temozolomide
20 mg CapsuleHDPE Bottle x 5’s Box of 1’s
RxVAT-exempt
Admac LifesciencesIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY43348
Apr 14, 2029
Temovex 250Temozolomide
250 mg CapsuleHDPE Bottle x 5’s (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY43347
Apr 14, 2029
TemoZiglaTemozolomide
100 mg CapsuleHDPE Bottle x 5's (Box of 5's)
RxVAT-exempt
Beta Drugs Ltd.India
Getmeds Philippines Inc.Importer: 2MG Incorporated
DRP-15722-01
Sep 13, 2029
TemozolTemozolamideVariant spelling
100 mg CapsuleHDPE Bottle x 5's in a Box
Rx
Intas Pharmaceuticals LimitedIndia
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DR-XY41933
Apr 8, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsules: – 5 mg: opaque white bodies with green caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo. The cap is imprinted with “TEMODAR.” – 20 mg: opaque white bodies with yellow caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.

The cap is imprinted with “TEMODAR.” – 100 mg: opaque white bodies with pink caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo. The cap is imprinted with “TEMODAR.” – 140 mg: opaque white bodies with blue caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.

The cap is imprinted with “TEMODAR.” – 180 mg: opaque white bodies with orange caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo. The cap is imprinted with “TEMODAR.” – 250 mg: opaque white bodies with white caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.

The cap is imprinted with “TEMODAR.” For injection: 100 mg white to light tan or light pink lyophilized powder for reconstitution in a single-dose vial. Capsules: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg. (3) For injection: 100 mg as a lyophilized powder in single-dose vial for reconstitution. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Myelosuppression: Monitor absolute neutrophil count (ANC) and platelet count prior to each cycle and during treatment. Geriatric patients and women have a higher risk of developing myelosuppression. (5.1, 8.5)
  • Hepatotoxicity: Fatal and severe hepatotoxicity have been reported. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately 2 to 4 weeks after the last dose of TEMODAR. (5.2)
  • Pneumocystis Pneumonia (PCP): Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (5.3)
  • Secondary Malignancies: Myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed. (5.4)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. Advise male patients with pregnant partners or female partners of reproductive potential to use condoms. (5.5, 8.1, 8.3)
  • Exposure to Opened Capsules: TEMODAR capsules should not be opened, chewed, or dissolved but should be swallowed whole with a glass of water. (5.6)
5.1 Myelosuppression

5.1 Myelosuppression Myelosuppression, including pancytopenia, leukopenia, and anemia, some with fatal outcomes, have occurred with TEMODAR [see Adverse Reactions (6.1, 6.2)]. In MK-7365-006, myelosuppression usually occurred during the first few cycles of therapy and was generally not cumulative. The median nadirs occurred at 26 days for platelets (range: 21 to 40 days) and 28 days for neutrophils (range: 1 to 44 days).

Approximately 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression. Obtain a complete blood count and monitor ANC and platelet counts before initiation of treatment and as clinically indicated during treatment.

When TEMODAR is used in combination with radiotherapy, obtain a complete blood count prior to initiation of treatment, weekly during treatment, and as clinically indicated [see Dosage and Administration (2.1, 2.2, 2.3)]. For severe myelosuppression, withhold TEMODAR and then resume at same or reduced dose, or permanently discontinue, based on occurrence [see Dosage and Administration (2.1, 2.2, 2.3)].

5.2 Hepatotoxicity

5.2 Hepatotoxicity Fatal and severe hepatotoxicity have been reported in patients receiving TEMODAR. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of TEMODAR.

5.3 Pneumocystis Pneumonia

5.3 Pneumocystis Pneumonia Pneumocystis pneumonia (PCP) has been reported in patients receiving TEMODAR. The risk of PCP is increased in patients receiving steroids or with longer treatment regimens of TEMODAR. For patients with newly diagnosed glioblastoma, provide PCP prophylaxis for all patients during the concomitant phase.

Continue PCP prophylaxis in patients who experience lymphopenia, until resolution to Grade 1 or less [see Dosage and Administration (2.1)]. Monitor all patients receiving TEMODAR for the development of lymphopenia and PCP.

5.4 Secondary Malignancies

5.4 Secondary Malignancies The incidence of secondary malignancies is increased in patients treated with TEMODAR-containing regimens. Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed following TEMODAR administration.

5.5 Embryo-Fetal Toxicity

5.5 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, TEMODAR can cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been reported in both pregnant patients and pregnant partners of male patients. Oral administration of temozolomide to rats and rabbits during the period of organogenesis resulted in embryolethality and polymalformations at doses less than the maximum human dose based on body surface area.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TEMODAR and for 6 months after the last dose. Because of potential risk of genotoxic effects on sperm, advise male patients with female partners of reproductive potential to use condoms during treatment with TEMODAR and for 3 months after the last dose.

Advise male patients not to donate semen during treatment with TEMODAR and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

5.6 Exposure to Opened Capsules

5.6 Exposure to Opened Capsules Advise patients not to open, chew or dissolve the contents of the TEMODAR capsules. Swallow capsules whole with a glass of water. If a capsule becomes damaged, avoid contact of the powder contents with skin or mucous membranes. In case of powder contact, wash affected area with water immediately [see Dosage and Administration (2.4)].

If TEMODAR capsules must be opened or the contents must be dissolved, this should be done by a professional trained in safe handling of hazardous drugs using appropriate equipment and safety procedures.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions (5.1)] Hepatotoxicity [see Warnings and Precautions (5.2)] Pneumocystis Pneumonia [see Warnings and Precautions (5.3)] Secondary Malignancies [see Warnings and Precautions (5.4)] The most common adverse reactions (≥20%) are: alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, and convulsions. (6.1)
  • The most common Grade 3 to 4 hematologic laboratory abnormalities (≥10%) in patients with anaplastic astrocytoma are: decreased lymphocytes, decreased platelets, decreased neutrophils, and decreased leukocytes. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Newly Diagnosed Glioblastoma The safety of TEMODAR was evaluated in study MK-7365-051 [see Clinical Studies (14.1)].

Severe or life-threatening adverse reactions occurred in 49% of patients treated with TEMODAR; the most common were fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia (5%). The most common adverse reactions (≥20%) in patients treated with TEMODAR were alopecia, fatigue, nausea, anorexia, headache, constipation, and vomiting.

Table 3 summarizes the adverse reactions in MK-7365-051. TABLE 3: Adverse Reactions (≥10%) in Patients with Newly Diagnosed Glioblastoma Adverse Reactions Concomitant Use Phase Maintenance Use Phase Radiation Therapy and TEMODAR N=288 One patient who was randomized to radiation therapy-only arm received radiation therapy and TEMODAR.

Radiation Therapy Alone N=285 TEMODAR N=224 All Grades (%) Grade ≥3 (%) All Grades (%) Grades ≥3 (%) All Grades (%) Grade ≥3 (%) Note: Grade 5 (fatal) adverse reactions are included in the Grade ≥3 column. Skin and Subcutaneous Tissue Alopecia 69 0 63 0 55 0 Rash 19 1 15 0 13 1 General Fatigue 54 7 49 5 61 9 Anorexia 19 1 9 <1 27 1 Headache 19 2 17 4 23 4 Gastrointestinal System Nausea 36 1 16 <1 49 1 Vomiting 20 <1 6 <1 29 2 Constipation 18 1 6 0 22 0 Diarrhea 6 0 3 0 10 1 Central and Peripheral Nervous System Convulsions 6 3 7 3 11 3 Clinically relevant adverse reactions in <10% of patients are presented below: Central & Peripheral Nervous System: memory impairment, confusion Eye: v ision blurred Gastrointestinal System: stomatitis, abdominal pain General: weakness, dizziness Immune System: allergic reaction Injury: radiation injury not otherwise specified Musculoskeletal System: arthralgia Platelet, Bleeding, & Clotting: thrombocytopenia Psychiatric: insomnia Respiratory System: coughing, dyspnea Special Senses Other: taste perversion Skin & Subcutaneous Tissue: dry skin, pruritus, erythema When laboratory abnormalities and adverse reactions were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic reactions were observed in 8% of patients, and Grade 3 or Grade 4 platelet abnormalities including thrombocytopenic reactions were observed in 14% of patients.

Newly Diagnosed Anaplastic Astrocytoma The safety of TEMODAR for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma was derived from published literature [see Clinical Studies (14.2)]. The safety of TEMODAR for the adjuvant treatment of patients with newly diagnosed anaplastic astrocytoma was consistent with the known safety profile of TEMODAR.

Refractory Anaplastic Astrocytoma The safety of TEMODAR was evaluated in study MK-7365-006 [see Clinical Studies (14.2)]. The most common adverse reactions (≥20%) were nausea, vomiting, headache, fatigue, constipation, and convulsions. Tables 4 and 5 summarize the adverse reactions and hematological laboratory abnormalities in MK-7365-006.

TABLE 4: Adverse Reactions (≥10%) in Patients with Refractory Anaplastic Astrocytoma Adverse Reactions TEMODAR N=158 All Reactions (%) Grades 3-4 (%) Gastrointestinal System Nausea 53 10 Vomiting 42 6 Constipation 33 1 Diarrhea 16 2 General Headache 41 6 Fatigue 34 4 Asthenia 13 6 Fever 13 2 Central and Peripheral Nervous System Convulsions 23 5 Hemiparesis 18 6 Dizziness 12 1 Coordination abnormal 11 1 Amnesia 10 4 Insomnia 10 0 Cardiovascular Edema peripheral 11 1 Resistance Mechanism Infection viral 11 0 Clinically relevant adverse reactions in <10% of patients are presented below: Central and Peripheral Nervous System: paresthesia, somnolence, paresis, urinary incontinence, ataxia, dysphasia, convulsions local, gait abnormal, confusion Endocrine: adrenal hypercorticism Gastrointestinal System: abdominal pain, anorexia General: back pain Metabolic: weight increase Musculoskeletal System: myalgia Psychiatric: anxiety, depression Reproductive Disorders: breast pain female Respiratory System: upper respiratory tract infection, pharyngitis, sinusitis, coughing Skin & Appendages: rash, pruritus Urinary System: urinary tract infection, micturition increased frequency Vision: diplopia, vision abnormal This term includes blurred vision; visual deficit; vision changes; and vision troubles. TABLE 5: Grade 3 to 4 Hematologic Laboratory Abnormalities That Worsened from Baseline in Patients with Refractory Anaplastic Astrocytoma TEMODAR Change from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment., Denominator range= 142, 158 (%) Decreased lymphocytes 55 Decreased platelets 19 Decreased neutrophils 14 Decreased leukocytes 11 Decreased hemoglobin 4 Hematological Toxicities for Advanced Gliomas In clinical trial experience with 110 to 111 females and 169 to 174 males (depending on measurements), females experienced higher rates of Grade 4 neutropenia (ANC <0.5 × 10 9 /L) and thrombocytopenia (<20 × 10 9 /L) than males in the first cycle of therapy (12% vs. 5% and 9% vs. 3%, respectively).

In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 10% (6/63) of patients >70 years experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients ≤70 years, 7% (62/871) and 6% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively.

Pancytopenia, leukopenia, and anemia also occurred. Injection Site Reactions Adverse reactions that were reported in 35 patients who received TEMODAR for injection were pain, irritation, pruritus, warmth, swelling, and erythema at infusion site; petechiae; and hematoma.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of TEMODAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.

Dermatologic: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Immune System: Hypersensitivity reactions, including anaphylaxis. Erythema multiforme, which resolved after discontinuation of TEMODAR and, in some cases, recurred upon rechallenge. Hematopoietic: Prolonged pancytopenia, which may result in aplastic anemia and fatal outcomes.

Hepatobiliary: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, and hepatitis. Infections: Serious opportunistic infections, including some cases with fatal outcomes, with bacterial, viral (primary and reactivated), fungal, and protozoan organisms. Pulmonary: Interstitial pneumonitis, pneumonitis, alveolitis, and pulmonary fibrosis.

Endocrine: Diabetes insipidus.

Adverse reaction frequency tables (US label) US FDA label
TABLE 3: Adverse Reactions (≥10%) in Patients with Newly Diagnosed Glioblastoma
Adverse ReactionsConcomitant Use PhaseMaintenance Use Phase
Radiation Therapy and TEMODAR N=288One patient who was randomized to radiation therapy-only arm received radiation therapy and TEMODAR.Radiation Therapy Alone N=285TEMODAR N=224
All Grades (%)Grade ≥3 (%)All Grades (%)Grades ≥3 (%)All Grades (%)Grade ≥3 (%)
Note: Grade 5 (fatal) adverse reactions are included in the Grade ≥3 column.
Skin and Subcutaneous Tissue
Alopecia690630550
Rash191150131
General
Fatigue547495619
Anorexia1919<1271
Headache192174234
Gastrointestinal System
Nausea36116<1491
Vomiting20<16<1292
Constipation18160220
Diarrhea6030101
Central and Peripheral Nervous System
Convulsions6373113
TABLE 4: Adverse Reactions (≥10%) in Patients with Refractory Anaplastic Astrocytoma
Adverse ReactionsTEMODAR N=158
All Reactions (%)Grades 3-4 (%)
Gastrointestinal System
Nausea5310
Vomiting426
Constipation331
Diarrhea162
General
Headache416
Fatigue344
Asthenia136
Fever132
Central and Peripheral Nervous System
Convulsions235
Hemiparesis186
Dizziness121
Coordination abnormal111
Amnesia104
Insomnia100
Cardiovascular
Edema peripheral111
Resistance Mechanism
Infection viral110
TABLE 5: Grade 3 to 4 Hematologic Laboratory Abnormalities That Worsened from Baseline in Patients with Refractory Anaplastic Astrocytoma
TEMODARChange from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.,Denominator range= 142, 158 (%)
Decreased lymphocytes55
Decreased platelets19
Decreased neutrophils14
Decreased leukocytes11
Decreased hemoglobin4

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], TEMODAR can cause fetal harm when administered to a pregnant woman. Available postmarketing reports describe cases of spontaneous abortions and congenital malformations, including polymalformations with central nervous system, facial, cardiac, skeletal, and genitourinary system anomalies with exposure to TEMODAR during pregnancy.

These cases report similar adverse developmental outcomes to those observed in animal studies. Administration of TEMODAR to rats and rabbits during the period of organogenesis caused numerous external, internal, and skeletal malformations at doses less than the maximum human dose based on body surface area (see Data). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Five consecutive days of oral administration of temozolomide at doses of 75 and 150 mg/m 2 (0.38 and 0.75 times the human dose of 200 mg/m 2) in rats and rabbits, respectively, during the period of organogenesis (Gestation Days 8-12) caused numerous malformations of the external and internal organs and skeleton in both species.

In rabbits, temozolomide at the 150 mg/m 2 dose (0.75 times the human dose of 200 mg/m 2) caused embryolethality as indicated by increased resorptions.

Mechanism of action

12.1 Mechanism of Action Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to DNA alkylation, mainly at the O 6 and N 7 positions of guanine, which causes DNA double strand breaks and results in programmed cell death.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Temozolomide exposure-response relationships and the time course of pharmacodynamic response are unknown.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.

Excretion Approximately 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 38% in urine and 0.8% in feces.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Following a single oral dose of 150 mg/m 2, the mean C max is 7.5 mcg/mL for temozolomide and 282 ng/mL for MTIC. The mean AUC is 23.4 mcg∙hr/mL for temozolomide and 864 ng∙hr/mL for MTIC. Following a single 90-minute intravenous infusion of 150 mg/m 2, the mean C max is 7.3 mcg/mL for temozolomide and 276 ng/mL for MTIC.

The mean AUC is 24.6 mcg∙hr/mL for temozolomide and 891 ng∙hr/mL for MTIC. Temozolomide exhibits linear kinetics over the therapeutic dosing range of 75 mg/m 2 /day to 250 mg/m 2 /day. Absorption The median T max is 1 hour. Effect of Food The mean temozolomide C max and AUC decreased by 32% and 9%, respectively, and median T max increased by 2-fold (from 1 to 2.25 hours) when TEMODAR capsules were administered after a modified high-fat breakfast (587 calories comprised of 1 fried egg, 2 strips of bacon, 2 slices of toast, 2 pats of butter, and 8 oz whole milk).

Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%). The mean percent bound of drug-related total radioactivity is 15%. Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours. Metabolism Temozolomide is spontaneously hydrolyzed at physiologic pH to the active species, MTIC and to temozolomide acid metabolite.

MTIC is further hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), which is known to be an intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. Cytochrome P450 enzymes play a minor role in the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide, the exposure to MTIC and AIC is 2.4% and 23%, respectively.

Excretion Approximately 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 38% in urine and 0.8% in feces. The majority of the recovered radioactivity in urine is unchanged temozolomide (6%), AIC (12%), temozolomide acid metabolite (2.3%), and unidentified polar metabolite(s) (17%). Specific Populations No clinically significant differences in the pharmacokinetics of temozolomide were observed based on age (range: 19 to 78 years), gender, smoking status (smoker vs. non-smoker), creatinine clearance (CLcr) of 36 to 130 mL/min/m 2, or mild to moderate hepatic impairment (Child Pugh class A and B).

The pharmacokinetics of temozolomide has not been studied in patients with CLcr <36 mL/min/m 2, end-stage renal disease on dialysis, or severe hepatic impairment (Child-Pugh class C). Drug Interaction Studies Clinical Studies and Model-Informed Approaches No clinically significant differences in the pharmacokinetics of temozolomide or MTIC were observed when co-administered with ranitidine.

No clinically significant differences in the clearance of temozolomide or MTIC were predicted when co-administered with the following drugs: valproic acid, dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, histamine-2-receptor antagonists, or phenobarbital.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. TEMODAR · Merck Sharp & Dohme LLC [US FDA-approved label, version 40, February 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=046a9011-3911-4d3f-a15f-fbb56d5aad56
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .